{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:23:18Z","timestamp":1790734998430,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171994"],"award-info":[{"award-number":["82171994"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Beijing Natural Science Foundation","award":["7232040"],"award-info":[{"award-number":["7232040"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11886-025-02230-x","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T04:21:50Z","timestamp":1744345310000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["68Ga-FAPI-04 PET\/CT for the Assessment of Light-Chain Cardiac Amyloidosis: A Promising Risk- Stratification Imaging Modality"],"prefix":"10.1007","volume":"27","author":[{"given":"Yaqi","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanlin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"key":"2230_CR1","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/CM9.0000000000002961","volume":"137","author":"K Shen","year":"2024","unstructured":"Shen K, Tian Z, Gao Y, et al. Chinese consensus on the diagnosis and treatment of immunoglobulin light-chain cardiac amyloidosis. Chin Med J (Engl). 2024;137:127\u20139.","journal-title":"Chin Med J (Engl)"},{"key":"2230_CR2","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1002\/ajh.26569","volume":"97","author":"MA Gertz","year":"2022","unstructured":"Gertz MA. Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment. Am J Hematol. 2022;97:818\u201329.","journal-title":"Am J Hematol"},{"key":"2230_CR3","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/j.jacc.2016.06.053","volume":"68","author":"RH Falk","year":"2016","unstructured":"Falk RH, Alexander KM, Liao R, Dorbala S. AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy. J Am Coll Cardiol. 2016;68:1323\u201341.","journal-title":"J Am Coll Cardiol"},{"key":"2230_CR4","doi-asserted-by":"publisher","first-page":"H149","DOI":"10.1152\/ajpheart.00073.2021","volume":"321","author":"KT Dittloff","year":"2021","unstructured":"Dittloff KT, Iezzi A, Zhong JX, Mohindra P, Desai TA, Russell B. Transthyretin amyloid fibrils alter primary fibroblast structure, function, and inflammatory gene expression. Am J Physiol Heart Circ Physiol. 2021;321:H149-h160.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2230_CR5","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.jacbts.2019.02.006","volume":"4","author":"C Humeres","year":"2019","unstructured":"Humeres C, Frangogiannis NG. Fibroblasts in the Infarcted, Remodeling, and Failing Heart. JACC Basic Transl Sci. 2019;4:449\u201367.","journal-title":"JACC Basic Transl Sci"},{"key":"2230_CR6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.trsl.2019.03.001","volume":"209","author":"S Park","year":"2019","unstructured":"Park S, Nguyen NB, Pezhouman A, Ardehali R. Cardiac fibrosis: potential therapeutic targets. Transl Res. 2019;209:121\u201337.","journal-title":"Transl Res"},{"key":"2230_CR7","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1016\/j.jcmg.2019.06.023","volume":"12","author":"M Fontana","year":"2019","unstructured":"Fontana M, \u0106orovi\u0107 A, Scully P, Moon JC. Myocardial Amyloidosis: The Exemplar Interstitial Disease. JACC Cardiovasc Imaging. 2019;12:2345\u201356.","journal-title":"JACC Cardiovasc Imaging"},{"key":"2230_CR8","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1182\/blood.2020008737","volume":"139","author":"G Palladini","year":"2022","unstructured":"Palladini G, Merlini G. How I treat AL amyloidosis. Blood. 2022;139:2918\u201330.","journal-title":"Blood"},{"key":"2230_CR9","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1182\/blood-2016-11-751628","volume":"129","author":"E Muchtar","year":"2017","unstructured":"Muchtar E, Gertz MA, Kumar SK, et al. Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. Blood. 2017;129:2111\u20139.","journal-title":"Blood"},{"key":"2230_CR10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41408-023-00789-8","volume":"13","author":"G Palladini","year":"2023","unstructured":"Palladini G, Sch\u00f6nland S, Merlini G, et al. The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018. Blood Cancer J. 2023;13:19.","journal-title":"Blood Cancer J"},{"key":"2230_CR11","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s12872-016-0311-6","volume":"16","author":"L Zhao","year":"2016","unstructured":"Zhao L, Tian Z, Fang Q. Diagnostic accuracy of cardiovascular magnetic resonance for patients with suspected cardiac amyloidosis: a systematic review and meta-analysis. BMC Cardiovasc Disord. 2016;16:129.","journal-title":"BMC Cardiovasc Disord"},{"key":"2230_CR12","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1161\/CIRCIMAGING.112.978627","volume":"6","author":"SM Banypersad","year":"2013","unstructured":"Banypersad SM, Sado DM, Flett AS, et al. Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study. Circ Cardiovasc Imaging. 2013;6:34\u20139.","journal-title":"Circ Cardiovasc Imaging"},{"key":"2230_CR13","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/1532-429X-15-92","volume":"15","author":"JC Moon","year":"2013","unstructured":"Moon JC, Messroghli DR, Kellman P, et al. Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. J Cardiovasc Magn Reson. 2013;15:92.","journal-title":"J Cardiovasc Magn Reson"},{"key":"2230_CR14","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jcmg.2017.01.025","volume":"11","author":"JA Lurz","year":"2018","unstructured":"Lurz JA, Luecke C, Lang D, et al. CMR-Derived Extracellular Volume Fraction as a Marker for Myocardial Fibrosis: The Importance of Coexisting Myocardial Inflammation. JACC Cardiovasc Imaging. 2018;11:38\u201345.","journal-title":"JACC Cardiovasc Imaging"},{"key":"2230_CR15","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/j.jcmg.2021.01.034","volume":"14","author":"X Li","year":"2021","unstructured":"Li X, Huang S, Miao H, et al. Multiparameter Cardiac Magnetic Resonance to Monitor Therapeutic Effect After Chemotherapy in Light Chain Amyloidosis Patients. JACC Cardiovasc Imaging. 2021;14:1485\u20137.","journal-title":"JACC Cardiovasc Imaging"},{"key":"2230_CR16","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.jcmg.2021.09.032","volume":"15","author":"SAM Cuddy","year":"2022","unstructured":"Cuddy SAM, Jerosch-Herold M, Falk RH, et al. Myocardial Composition in Light-Chain Cardiac Amyloidosis More Than 1 Year After Successful Therapy. JACC Cardiovasc Imaging. 2022;15:594\u2013603.","journal-title":"JACC Cardiovasc Imaging"},{"key":"2230_CR17","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1001\/jama.2020.5493","volume":"324","author":"MA Gertz","year":"2020","unstructured":"Gertz MA, Dispenzieri A. Systemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic Review. JAMA. 2020;324:79\u201389.","journal-title":"JAMA"},{"key":"2230_CR18","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.blre.2017.03.002","volume":"31","author":"C Zhang","year":"2017","unstructured":"Zhang C, Huang X, Li J. Light chain amyloidosis: Where are the light chains from and how they play their pathogenic role? Blood Rev. 2017;31:261\u201370.","journal-title":"Blood Rev"},{"key":"2230_CR19","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1161\/01.RES.0000126569.75419.74","volume":"94","author":"DA Brenner","year":"2004","unstructured":"Brenner DA, Jain M, Pimentel DR, et al. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res. 2004;94:1008\u201310.","journal-title":"Circ Res"},{"key":"2230_CR20","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.jchf.2014.03.009","volume":"2","author":"S Dorbala","year":"2014","unstructured":"Dorbala S, Vangala D, Bruyere J, et al. Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis. JACC Heart Fail. 2014;2:358\u201367.","journal-title":"JACC Heart Fail"},{"key":"2230_CR21","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1161\/CIRCULATIONAHA.105.573865","volume":"113","author":"SH Ahmed","year":"2006","unstructured":"Ahmed SH, Clark LL, Pennington WR, et al. Matrix metalloproteinases\/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation. 2006;113:2089\u201396.","journal-title":"Circulation"},{"key":"2230_CR22","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1161\/CIRCHEARTFAILURE.108.788687","volume":"1","author":"A Biolo","year":"2008","unstructured":"Biolo A, Ramamurthy S, Connors LH, et al. Matrix metalloproteinases and their tissue inhibitors in cardiac amyloidosis: relationship to structural, functional myocardial changes and to light chain amyloid deposition. Circ Heart Fail. 2008;1:249\u201357.","journal-title":"Circ Heart Fail"},{"key":"2230_CR23","doi-asserted-by":"publisher","first-page":"e005868","DOI":"10.1161\/JAHA.112.005868","volume":"2","author":"K Tanaka","year":"2013","unstructured":"Tanaka K, Essick EE, Doros G, et al. Circulating matrix metalloproteinases and tissue inhibitors of metalloproteinases in cardiac amyloidosis. J Am Heart Assoc. 2013;2:e005868.","journal-title":"J Am Heart Assoc"},{"key":"2230_CR24","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1002\/ejhf.1039","volume":"20","author":"CS Siegismund","year":"2018","unstructured":"Siegismund CS, Escher F, Lassner D, et al. Intramyocardial inflammation predicts adverse outcome in patients with cardiac AL amyloidosis. Eur J Heart Fail. 2018;20:751\u20137.","journal-title":"Eur J Heart Fail"},{"key":"2230_CR25","doi-asserted-by":"publisher","first-page":"23313","DOI":"10.1038\/s41598-024-74289-5","volume":"14","author":"P Simon","year":"2024","unstructured":"Simon P, Behrens H-M, Kristen A, R\u00f6cken C. Myocardial inflammatory cells in cardiac amyloidosis. Sci Rep. 2024;14:23313.","journal-title":"Sci Rep"},{"key":"2230_CR26","doi-asserted-by":"publisher","first-page":"e020358","DOI":"10.1161\/JAHA.120.020358","volume":"10","author":"A Pucci","year":"2021","unstructured":"Pucci A, Aimo A, Musetti V, et al. Amyloid Deposits and Fibrosis on Left Ventricular Endomyocardial Biopsy Correlate With Extracellular Volume in Cardiac Amyloidosis. J Am Heart Assoc. 2021;10:e020358.","journal-title":"J Am Heart Assoc"},{"key":"2230_CR27","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1016\/j.jcmg.2022.08.019","volume":"15","author":"S Dorbala","year":"2022","unstructured":"Dorbala S. Fibroblast Activation: A Novel Mechanism of Heart Failure in Light Chain Cardiac Amyloidosis? JACC Cardiovasc Imaging. 2022;15:1971\u20133.","journal-title":"JACC Cardiovasc Imaging"},{"key":"2230_CR28","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2967\/jnumed.111.102053","volume":"54","author":"G Antoni","year":"2013","unstructured":"Antoni G, Lubberink M, Estrada S, et al. In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET. J Nucl Med. 2013;54:213\u201320.","journal-title":"J Nucl Med"},{"key":"2230_CR29","doi-asserted-by":"publisher","first-page":"20s","DOI":"10.2967\/jnumed.122.264866","volume":"64","author":"S Dorbala","year":"2023","unstructured":"Dorbala S, Kijewski MF. Molecular Imaging of Systemic and Cardiac Amyloidosis: Recent Advances and Focus on the Future. J Nucl Med. 2023;64:20s\u20138s.","journal-title":"J Nucl Med"},{"key":"2230_CR30","doi-asserted-by":"publisher","first-page":"965","DOI":"10.2967\/jnumed.120.245381","volume":"61","author":"A Masri","year":"2020","unstructured":"Masri A, Bukhari S, Eisele YS, Soman P. Molecular Imaging of Cardiac Amyloidosis. J Nucl Med. 2020;61:965\u201370.","journal-title":"J Nucl Med"},{"key":"2230_CR31","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.jcmg.2020.05.031","volume":"14","author":"D Genovesi","year":"2021","unstructured":"Genovesi D, Vergaro G, Giorgetti A, et al. [18F]-Florbetaben PET\/CT for Differential Diagnosis Among Cardiac Immunoglobulin Light Chain, Transthyretin Amyloidosis, and Mimicking Conditions. JACC Cardiovasc Imaging. 2021;14:246\u201355.","journal-title":"JACC Cardiovasc Imaging"},{"key":"2230_CR32","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.2967\/jnumed.121.263033","volume":"63","author":"YJ Choi","year":"2022","unstructured":"Choi YJ, Koh Y, Lee HJ, et al. Independent Prognostic Utility of (11)C-Pittsburgh Compound B PET in Patients with Light-Chain Cardiac Amyloidosis. J Nucl Med. 2022;63:1064\u20139.","journal-title":"J Nucl Med"},{"key":"2230_CR33","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.jacc.2019.11.037","volume":"75","author":"SP Lee","year":"2020","unstructured":"Lee SP, Suh HY, Park S, et al. Pittsburgh B Compound Positron Emission Tomography in Patients With AL Cardiac Amyloidosis. J Am Coll Cardiol. 2020;75:380\u201390.","journal-title":"J Am Coll Cardiol"},{"key":"2230_CR34","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/j.jcmg.2020.02.025","volume":"13","author":"SAM Cuddy","year":"2020","unstructured":"Cuddy SAM, Bravo PE, Falk RH, et al. Improved Quantification of Cardiac Amyloid Burden in Systemic Light Chain Amyloidosis: Redefining Early Disease? JACC Cardiovasc Imaging. 2020;13:1325\u201336.","journal-title":"JACC Cardiovasc Imaging"},{"key":"2230_CR35","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.jcmg.2024.05.002","volume":"17","author":"OF Clerc","year":"2024","unstructured":"Clerc OF, Datar Y, Cuddy SA, et al. Prognostic Value of Left Ventricular 18F-Florbetapir Uptake in Systemic Light-Chain Amyloidosis. JACC Cardiovasc Imaging. 2024;17:911\u201322.","journal-title":"JACC Cardiovasc Imaging"},{"key":"2230_CR36","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1161\/circ.104.14.1594","volume":"104","author":"R Liao","year":"2001","unstructured":"Liao R, Jain M, Teller P, et al. Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation. 2001;104:1594\u20137.","journal-title":"Circulation"},{"key":"2230_CR37","doi-asserted-by":"publisher","first-page":"4188","DOI":"10.1073\/pnas.0912263107","volume":"107","author":"J Shi","year":"2010","unstructured":"Shi J, Guan J, Jiang B, et al. Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway. Proc Natl Acad Sci U S A. 2010;107:4188\u201393.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2230_CR38","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/nrcardio.2009.199","volume":"7","author":"SWM van den Borne","year":"2010","unstructured":"van den Borne SWM, Diez J, Blankesteijn WM, Verjans J, Hofstra L, Narula J. Myocardial remodeling after infarction: the role of myofibroblasts. Nat Rev Cardiol. 2010;7:30\u20137.","journal-title":"Nat Rev Cardiol"},{"key":"2230_CR39","first-page":"6406","volume":"46","author":"WJ Rettig","year":"1986","unstructured":"Rettig WJ, Chesa PG, Beresford HR, et al. Differential expression of cell surface antigens and glial fibrillary acidic protein in human astrocytoma subsets. Cancer Res. 1986;46:6406\u201312.","journal-title":"Cancer Res"},{"key":"2230_CR40","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/prca.201300095","volume":"8","author":"EJ Hamson","year":"2014","unstructured":"Hamson EJ, Keane FM, Tholen S, Schilling O, Gorrell MD. Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy. Proteomics Clin Appl. 2014;8:454\u201363.","journal-title":"Proteomics Clin Appl"},{"key":"2230_CR41","doi-asserted-by":"publisher","first-page":"e221052","DOI":"10.1148\/radiol.221052","volume":"306","author":"L Wang","year":"2023","unstructured":"Wang L, Wang Y, Wang J, et al. Myocardial Activity at (18)F-FAPI PET\/CT and Risk for Sudden Cardiac Death in Hypertrophic Cardiomyopathy. Radiology. 2023;306:e221052.","journal-title":"Radiology"},{"key":"2230_CR42","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s00259-021-05577-9","volume":"49","author":"BX Chen","year":"2022","unstructured":"Chen BX, Xing HQ, Gong JN, et al. Imaging of cardiac fibroblast activation in patients with chronic thromboembolic pulmonary hypertension. Eur J Nucl Med Mol Imaging. 2022;49:1211\u201322.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2230_CR43","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.2967\/jnumed.121.263555","volume":"63","author":"J Diekmann","year":"2022","unstructured":"Diekmann J, Koenig T, Thackeray JT, et al. Cardiac Fibroblast Activation in Patients Early After Acute Myocardial Infarction: Integration with MR Tissue Characterization and Subsequent Functional Outcome. J Nucl Med. 2022;63:1415\u201323.","journal-title":"J Nucl Med"},{"key":"2230_CR44","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.2967\/jnumed.122.265147","volume":"64","author":"J Diekmann","year":"2023","unstructured":"Diekmann J, Neuser J, R\u00f6hrich M, et al. Molecular Imaging of Myocardial Fibroblast Activation in Patients with Advanced Aortic Stenosis Before Transcatheter Aortic Valve Replacement: A Pilot Study. J Nucl Med. 2023;64:1279\u201386.","journal-title":"J Nucl Med"},{"key":"2230_CR45","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1148\/radiol.211951","volume":"303","author":"W Guo","year":"2022","unstructured":"Guo W, Chen H. (68)Ga FAPI PET\/MRI in Cardiac Amyloidosis. Radiology. 2022;303:51.","journal-title":"Radiology"},{"key":"2230_CR46","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.abm0594","volume":"375","author":"JG Rurik","year":"2022","unstructured":"Rurik JG, Tomb\u00e1cz I, Yadegari A, et al. CAR T cells produced in vivo to treat cardiac injury. Science. 2022;375:91\u20136.","journal-title":"Science"},{"key":"2230_CR47","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1161\/CIRCRESAHA.122.320781","volume":"132","author":"Y Sun","year":"2023","unstructured":"Sun Y, Ma M, Cao D, et al. Inhibition of Fap Promotes Cardiac Repair by Stabilizing BNP. Circ Res. 2023;132:586\u2013600.","journal-title":"Circ Res"},{"key":"2230_CR48","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1016\/j.jcmg.2022.06.004","volume":"15","author":"X Wang","year":"2022","unstructured":"Wang X, Guo Y, Gao Y, et al. Feasibility of 68Ga-Labeled Fibroblast Activation Protein Inhibitor PET\/CT in Light-Chain Cardiac Amyloidosis. JACC Cardiovasc Imaging. 2022;15:1960\u201370.","journal-title":"JACC Cardiovasc Imaging"},{"key":"2230_CR49","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1016\/j.jcmg.2022.10.001","volume":"15","author":"V Dilsizian","year":"2022","unstructured":"Dilsizian V, Chandrashekhar Y. Molecular Imaging: New Promises. JACC Cardiovasc Imaging. 2022;15:2019\u201321.","journal-title":"JACC Cardiovasc Imaging"},{"key":"2230_CR50","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jcmg.2024.10.001","volume":"18","author":"X Wang","year":"2025","unstructured":"Wang X, Shen K, Zhang Y, et al. Molecular Stratification of Light-Chain Cardiac Amyloidosis With 18F-Florbetapir and 68Ga-FAPI-04 for Enhanced Prognostic Precision. JACC Cardiovasc Imaging. 2025;18:323\u201336.","journal-title":"JACC Cardiovasc Imaging"},{"key":"2230_CR51","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s11886-023-01869-8","volume":"25","author":"MF Mayola","year":"2023","unstructured":"Mayola MF, Thackeray JT. The potential of fibroblast activation protein-targeted imaging as a biomarker of cardiac remodeling and injury. Curr Cardiol Rep. 2023;25:515\u201323.","journal-title":"Curr Cardiol Rep."}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-025-02230-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-025-02230-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-025-02230-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T09:02:37Z","timestamp":1772096557000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-025-02230-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2230"],"URL":"https:\/\/doi.org\/10.1007\/s11886-025-02230-x","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,11]]},"assertion":[{"value":"24 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"83"}}